14-day Premium Trial Subscription Try For FreeTry Free
$4.21
+0.0100 (+0.238%)
At Close: May 02, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $3.20 $4.97 Thursday, 2nd May 2024 ALDX stock ended at $4.21. This is 0.238% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 3.57% from a day low at $4.09 to a day high of $4.24.
90 days $2.71 $4.97
52 weeks $1.42 $11.97

Historical Aldeyra Therapeutics prices

Date Open High Low Close Volume
May 10, 2021 $12.48 $12.65 $12.01 $12.04 1 104 859
May 07, 2021 $12.43 $12.74 $12.21 $12.48 1 311 502
May 06, 2021 $11.72 $12.15 $11.28 $12.05 1 472 998
May 05, 2021 $12.70 $12.80 $11.83 $11.97 1 635 102
May 04, 2021 $12.27 $12.33 $11.62 $11.99 1 704 361
May 03, 2021 $12.56 $13.07 $12.29 $12.49 1 735 753
Apr 30, 2021 $12.36 $12.98 $12.29 $12.57 1 862 400
Apr 29, 2021 $12.98 $13.48 $12.33 $12.51 7 718 839
Apr 28, 2021 $14.13 $14.43 $12.98 $13.93 5 907 911
Apr 27, 2021 $12.89 $15.95 $12.79 $14.85 83 815 059
Apr 26, 2021 $10.61 $11.13 $10.50 $11.11 694 861
Apr 23, 2021 $10.76 $10.80 $10.12 $10.60 1 631 641
Apr 22, 2021 $11.49 $11.79 $10.42 $10.44 1 471 710
Apr 21, 2021 $11.05 $11.84 $10.90 $11.84 369 254
Apr 20, 2021 $10.90 $11.27 $10.81 $11.02 429 861
Apr 19, 2021 $11.22 $11.49 $10.89 $10.90 362 670
Apr 16, 2021 $11.49 $11.53 $10.90 $11.28 489 411
Apr 15, 2021 $11.85 $12.09 $11.39 $11.57 885 573
Apr 14, 2021 $11.36 $12.00 $11.08 $11.75 492 251
Apr 13, 2021 $11.73 $11.79 $10.90 $11.36 620 874
Apr 12, 2021 $12.01 $12.04 $11.51 $11.71 484 260
Apr 09, 2021 $12.46 $12.60 $12.02 $12.04 386 849
Apr 08, 2021 $12.50 $12.78 $12.28 $12.53 394 884
Apr 07, 2021 $12.44 $12.84 $12.35 $12.35 447 510
Apr 06, 2021 $12.64 $12.83 $12.42 $12.50 446 155
Click to get the best stock tips daily for free!

About Aldeyra Therapeutics

Aldeyra Therapeutics Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria... ALDX Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT